HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer

Non-small cell lung cancer (NSCLC) ranks the first in incidence and mortality among malignant tumors in China. Molecular targeted therapies such as gefitinib, an oral inhibitor of the epidermal growth factor receptor tyrosine kinase, have shown significant benefits in patients with advanced NSCLC. H...

Full description

Bibliographic Details
Main Authors: Lei Tianyao, Huang Jiali, Xie Fei, Gu Jingyao, Cheng Zhixiang, Wang Zhaoxia
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2022-04-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
gefitinib resistance
high-mobility group box 1
autophagy
non-small cell lung cancer
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2022023

Internet

https://www.sciengine.com/doi/10.3724/abbs.2022023

Similar Items